Pfizer Inc (PFE) Stock Analysis
Verdict: HOLD
High dividend yield of 5.38% and insider buying cushion patent cliffs, but declining long-term consensus EPS caps near-term upside.
Investment score: 61/100
Analysis as of
Is Pfizer Inc stock worth reviewing? AI model thesis
The AI model evaluates Pfizer as a Hold at $28.57. A attractive dividend yield of 5.38% and strong insider sentiment are balanced by high debt levels ($67.42B) and consensus top-line headwinds past 2027.
7-factor investment score
- Valuation: 52/100 (weight 20%)
- Financial Health: 48/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 58/100 (weight 15%)
Pfizer Inc opportunities and risks
What speaks for PFE
- Substantial Dividend Yield and Cash Flow Generation
What speaks against PFE
- Patent Cliff Pressure on Long-Term Revenue
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PFE | 37.8x | 2.6x | 17.8x | 71.3% | 6.8% | 6.7% |
| LLY | 41.3x | 14.6x | 34.3x | 84.0% | 33.5% | 1.7% |
| JNJ | 31.6x | 6.7x | 20.4x | 70.5% | 21.5% | 2.8% |
| MRK | 124.2x | 5.8x | 31.3x | 75.4% | 4.8% | 4.2% |
| BMY | 15.0x | 2.8x | 10.4x | 70.2% | 18.9% | 8.2% |
| RPRX | 25.8x | 10.8x | 20.8x | 89.4% | 32.1% | 10.8% |
| Peer median | 31.6x | 6.7x | 20.8x | 75.4% | 21.5% | 4.2% |
Frequently asked questions about Pfizer Inc (PFE)
Is PFE stock a good investment?
The cached TradeMates AI model rates Pfizer Inc as HOLD with an investment score of 61/100. The AI model evaluates Pfizer as a Hold at $28.57. A attractive dividend yield of 5.38% and strong insider sentiment are balanced by high debt levels ($67.42B) and consensus top-line headwinds past 2027. This is algorithmic model output, not personal investment advice.
Is PFE stock a buy?
The TradeMates model verdict for PFE is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.